ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer

Published Date: 06 Jun 2025

For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) yields better event-free survival outcomes than FLOT alone, according ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

2.

Year in Review: Non-Small Cell Lung Cancer

3.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.

4.

Independent Risk Factors for "Deaths of Despair" Found.

5.

In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot